Correlation between PET/CT parameters and KRAS expression in colorectal cancer

Area of Science:

• Oncology
• Radiology
• Molecular Diagnostics

Background:

• KRAS mutations are crucial in colorectal cancer (CRC) pathogenesis and treatment decisions.
• Accurate identification of KRAS mutation status is vital for personalized CRC therapy.
• Current methods for determining KRAS status can be invasive or time-consuming.

Purpose of the Study:

• To investigate the association between F-FDG PET/CT parameters and KRAS mutation status in CRC.
• To evaluate the potential of non-invasive PET/CT imaging to predict KRAS mutations.
• To correlate imaging biomarkers with genomic expression in CRC patients.

Main Methods:

• A cohort of 121 CRC patients undergoing preoperative PET/CT was analyzed.
• Key PET/CT parameters including SUVmax, metabolic tumor volume, total lesion glycolysis, and tumor width (TW) were measured.
• Statistical analyses, including Mann-Whitney U test and logistic regression, were used to correlate PET/CT parameters with KRAS mutation status.

Main Results:

• CRC tumors with mutated KRAS showed significantly higher SUVmax and increased FDG uptake.
• Multivariate analysis identified SUVmax and TW40% (40% threshold for maximal uptake of TW) as significant predictors of KRAS mutations.
• SUVmax was more accurate for predicting KRAS mutations in colon/sigmoid cancers, while TW40% was more accurate in rectal cancers.

Conclusions:

• SUVmax and TW40% are imaging biomarkers associated with KRAS mutations in CRC.
• FDG PET/CT parameters can serve as a valuable adjunct to genomic analysis for assessing KRAS expression.
• Non-invasive PET/CT imaging offers a promising approach to complement molecular diagnostics in CRC.